Ixekizumab, an IL-17A inhibitor, is commonly used to treat moderate-to-severe plaque psoriasis and psoriatic arthritis, with a well-documented risk of mucocutaneous Candida infections, though its role in bacterial infections is less defined. Here, IL17A is linked to candidiasis.